Rare APOE Variants Reduce Alzheimer’s Risk by More Than 60%

Rare APOE Variants Reduce Alzheimer’s Risk by More Than 60%

Two rare mutations in the APOE gene ― APOE ε4 (R251G) and APOE ε3 (V236E) ― dramatically reduce the risk of developing Alzheimer’s disease (AD), results of a large genetic association study show.

APOE ε4 (R251G) is a newly identified, risk-modifying variant in APOE’s lipid binding region that is inherited with APOE ε4 and reduces the risk of AD by more than 60%.

“The APOE ε4 is the strongest genetic risk factor for late-onset AD, and identifying genetic variants counterbalancing its associated risk may shed new light on its role in driving AD,” Yann Le Guen, PhD, Department of Neurology and Neurological Sciences, Stanford University, California, told Medscape Medical News.

“Our findings will hopefully lead to the development of new drugs mimicking the effect of these genetic variants on APOE to reduce the impact of APOE ε4 on AD pathology,” Le Guen said.

The other variant, APOE ε3 (V236E), is co-inherited with APOE ε3 and reduces the risk of AD by more than 50%. It was previously shown to be associated with decreased AD in smaller cohorts, but more robustly so in this larger dataset, the authors say.

The study was published online May 31 in JAMA Neurology.

Novel Drug Targets

Both R251G and V236E are missense variants that change a single amino acid in the APOE protein sequence. They are exceedingly rare; the estimated population frequency is less than 0.1%.

To identify these rare protective variants, the researchers mined genetic data from multiple studies involving 544,384 individuals, including 67,896 people with AD, 28,484 proxy AD case persons (individuals with a first-degree relative with AD), and 340,306 healthy control persons.

The two variants were associated with a more than twofold reduction in AD risk, with an odds ratio of 0.44 for R251G and 0.37 for V236E.

In addition, among V236E carriers, there was a 10.5-year delay in the age of AD onset compared with noncarriers; among R251G carriers, there was a trend toward a 6-year delay.

With both variants, the cumulative incidence of AD grew more slowly with age.

The researchers note that the location of these protective variants ― near the carboxyl-terminal portion of APOE ― adds support to studies suggesting that the C-terminal domain plays an important role in AD pathogenesis.

“The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE,” they write.

“We hope that subsequent work will elucidate the mechanisms behind this protective effect, paving the way for novel therapeutics, such as small molecules, that reduce AD pathology and delay AD onset,” Le Guen told Medscape Medical News.

Countering APOE ε4 Risk

In a linked editorial, Gil Rabinovici, MD, and Dena Dubal, MD, PhD, with the Department of Neurology, University of California, San Francisco, note that while these variants in APOE are very rare, “the magnitude of their observed effects is large and thus will further our understanding of the biological pathways through which APOE profoundly modifies the risk of AD.”

Putting the findings into larger and clinical context, Rabinovici and Dubal note that having R251G in association with APOE ε4, or V236E in association with APOE ε3, resulted in a protective effect “similar to or even superior to the degree of protection provided by APOE ε2. In the case of R251G, a single amino acid substitution negated the risk of carrying APOE ε4.

“A better understanding of these pathways will likely identify novel therapeutic targets that can delay or possibly prevent disease even in individuals at high genetic risk owing to APOE ε4 or autosomal dominant pathogenic gene variants, or even individuals with late-onset AD,” they add.

The study was funded by National Institutes of Health, the European Union’s Horizon 2020 research and innovation funding program, the Alzheimer’s Association, the Iqbal Farrukh and Asad Jamal Fund, and the EU Joint Programme–Neurodegenerative Disease Research. Le Guen has disclosed no relevant financial relationships. A complete list of authors’ disclosures is available with the original article. Rabinovici and Dubal are associate editors of JAMA Neurology.

JAMA Neurology. Published online May 31, 2022. Abstract, Editorial

For more Medscape Neurology news, join us on Facebook and Twitter.

Read More


Leave your thought here

Your email address will not be published.